Pharma Companies Must Assure Their ‘House Is In Order’ As FTC Takes Aim At Deceptive Endorsements
Executive Summary
US FTC sends notices to more than 700 companies about penalties they will face if they use deceptive endorsements and testimonials to promote their products. Industry experts discuss impact of surprising action and cautions to take in teaming up with influencers.
You may also be interested in...
FTC Weighing Trade Rule On Fake Endorsements, Including By ‘Patient Ambassadors’
If the commission does develop a rule, it would provide a vehicle for stronger enforcement in the area.
FTC Weighing Trade Rule On Fake Endorsements, Including By ‘Patient Ambassadors’
If the commission does develop a rule, it would provide a vehicle for stronger enforcement in the area.
Despite Few Actions On Rx Drug Promos, US FDA Increased Engagement With Stakeholders Last Year
Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.